Meeting objectives

- Update on HIV clinical research relating to women in resource-poor countries including clinical trial design, defining appropriate endpoints and lessons learned.

- Develop priorities for research that ILF can address, building on industry investment and areas of future research that inform HIV treatment for women.

- Develop and support an investigator-led research agenda that industry can support.

11.00am Buffet breakfast

Agenda

11.15am Why focus on women?  
*Introduced by Pedro Cahn*

11.30am Epidemiological update on HIV, women and children  
*Quarraisha Abdool Karim, University of Kwazulu-Natal, South Africa*

11.35am HIV clinical research in women: status update  
*Purnima Madhivanan, Managing Director, Public Health Research Institute of India and Director of the Prerana Reproductive Health Clinic located at C.S.I. Holdsworth Memorial Hospital, Mysore, India and UC Berkley, USA*

11.45am Clinical pharmacology of antiretroviral therapy in women: How much do we know?  
*Angela D.M. Kashuba, Associate Professor, School of Pharmacy and Director of the UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core, University of North Carolina at Chapel Hill, USA*

12.00pm Q&A: facilitator, Pedro Cahn

12.10pm Industry roundtable: commitment to research on women: facilitator, Elly Katabira

12.30pm Whole group discussion: facilitator, Lynne Mofenson, NIH, USA

1.10pm ILF planning and closing remarks, Elly Katabira

1.15pm Meeting close
Speaker profiles

Quarraisha Abdool Karim
Quarraisha Abdool Karim is an infectious diseases epidemiologist whose main research interests are in understanding the evolving HIV epidemic in South Africa; factors influencing acquisition of HIV infection in adolescent girls; and sustainable strategies to introduce HAART in resource-constrained settings. She is an Associate Professor in Epidemiology at the Mailman School of Public Health. In addition, she is the Director of the Columbia-University Southern African Fogarty AIDS International Training and Research Programme in Durban, South Africa and is Head of the CAPRISA Woman and AIDS programme. She is also an Associate Professor in Public Health and Family Medicine at the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, South Africa. She is an Executive Director of the International Partnership for Microbicides, a newly established not for profit organization to fast track microbicide development. She serves as a temporary consultant to WHO, UNAIDS and UNDP on several HIV/AIDS related expert committees in relation to gender, ethics, vaccines, treatment and research capacity building.

Angela D. M. Kashuba
Angela Kashuba is Associate Professor of Pharmacy at the University of North Carolina at Chapel Hill. Her pharmacy training is from the University of Toronto and the University of Buffalo. She is a Diplomate of the American Board of Clinical Pharmacology, and Director of the UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core Laboratory. Dr Kashuba’s research experiences include understanding and predicting drug interactions with small molecules and proteins in vitro and in vivo, and population pharmacokinetic modelling. Most recently, she has been focused on understanding the intracellular and extracellular pharmacokinetics and pharmacodynamics of systemic and topical antiretroviral agents in the genital tract and tissues as a means to select optimal drugs for use in pre- and post-exposure prophylaxis regimens.

Purnima Madhivanan
Purnima Madhivanan received her medical training at Mysore Medical College in Mysore, India. She earned a Masters in Public Health and PhD in Epidemiology from the University of California, Berkeley. She was the recipient of UC Berkley’s Women Global Health Scholarship aimed at redressing worldwide gender inequalities in science and academia. Dr Madhivanan has established clinics for women and children in Chennai and Mysore, India mindful of the obstacles that prevent women from accessing services as well as the need to develop sound infrastructural support for female scientists and physicians in developing country settings. She is currently the Managing Director of Public Health Research Institute of India and the Director of the Prerana Reproductive Health Clinic located at C.S.I. Holdsworth Memorial Hospital in Mysore, India. She has published widely on women’s health including sexual behaviour, sexually transmitted diseases and HIV transmission.

Lynne Mofenson
Lynne Mofenson is an infectious disease specialist and paediatrician who joined the Pediatric, Adolescent & Maternal AIDS (PAMA) Branch in 1989. As Branch Chief, she is responsible for scientific direction and clinical trials in domestic and international pediatric, adolescent, and maternal HIV infection, disease, and AIDS. She is also project officer for the NICHD-funded multi-site Domestic and International Pediatric/Perinatal HIV Clinical Studies Network, which conducts clinical trials in treatment and management of HIV infection in infants, children, adolescents, and women both domestically and internationally. Dr Mofenson serves as Executive Secretary for the US Public Health Service guidelines for treatment of HIV-infected children, treatment of HIV-infected pregnant women and prevention of mother to child HIV transmission, and provides consultation to the WHO on treatment guidelines in resource-limited countries.
Invited participants

Quarraisha Abdool Karim, University of Kwazulu-Natal, South Africa and Columbia University, USA
Keith Alcorn, Department for International Development, UK
Jean Anderson, Johns Hopkins, USA
Adriana Andrade, Johns Hopkins, USA
Linda-Gail Bekker, University of Cape Town, South Africa
Terry Blaschke, Stanford University, USA
Charles Boucher, Utrecht Medical School, the Netherlands
Pedro Cahn, Fundación Huesped and IAS, Argentina
Edmund Caparelli, UCSD, USA
Ward Cates, Family Health International, USA
Ben Cheng, Collaborative Forum for HIV Research, USA
Susan Chuck, Abbott Laboratories, USA
Myron Cohen, University of North Carolina, Chapel Hill, USA
Judith Currier, UCLA CARE Center, USA
Carl Dieffenbach, NIH, USA
Rob Dintruff, Abbott Laboratories, USA
Ernest Ekong, Military Reference Hospital, Nigeria
Thomas Fischer, Boehringer Ingelheim, Germany
Amy Flood, Gilead Sciences, USA
Mary Glenn Fowler, Johns Hopkins University, USA and Uganda
Bob Grant, University of California San Francisco, USA
Geeta Gupta, ICRW
David Haerry, European AIDS Treatment Group, Switzerland
Yasmin Halima, Consultant, IAS, USA
Cate Hankins, UNAIDS, Switzerland
Shirin Heidari, IAS, Switzerland
John Idoko, Nigeria
Angela Kashuba, University of North Carolina, Chapel Hill, USA
Elly Katabira, Makerere University, Uganda
Michel Kazatchkine, Global Fund, Switzerland
Ann Kolokathis, BMS, USA
Rodney Kort, Consultant, IAS, Canada
Joep Lange, Academic Medical Centre and IAS, Netherlands
Cecile Le Camus, Vertex Pharmaceuticals Europe, France
Nicolai Lohse, UNAIDS, Switzerland
Shahin Lockman, Harvard, USA
Purnima Madhivanan, UC Berkley, USA and Public Health Research Institute, India
Karen Manson, Tibotec, Belgium
Louise Martin-Carpenter, Glaxo SmithKline, USA
Mark Mirochnick, Boston University, USA
Souleymane Mboup, Cheikh Anta Diop University, Senegal
Ron McInnis, IAS, Switzerland
Lynne Mofenson, NIH, USA
Julio Montaner, BC Centre for Excellence in HIV, Canada
Jeff Nadler, NIH, USA
Annalene Nel from International Partnership for Microbicides, USA
Marie-Louis Newell, University of Kwazulu Natal, South Africa and Institute of Child Health, UK
Ighovwerha Ofotokun, Emory University, USA
Wim Parys, Tibotec, Belgium
Lynn Paxton, CDC, USA
Carla Pettinelli, NIH, USA
Tom Quinn, Johns Hopkins University, USA
Michael Rabbow, Boehringer Ingelheim, Germany
Sib Rahim, Abbott, USA
Marcus Reidenberg, Essential Medicines List, WHO, Switzerland
Renee Ridzon, Bill & Melinda Gates Foundation, USA
Jim Rooney, Gilead, USA
Zeda Rosenberg, International Partnership for Microbicides, USA
Paul Schaper, Abbott Laboratories, USA
Andy Schmeltz, Pfizer, USA
Jean-Marc Steens, Glaxo SmithKline, UK
Paul Stoffels, Johnson & Johnson, USA
Virginie Supervie, UCLA, USA
Randy Tressler, Pfizer, USA
Mitchell Warren, AIDS Vaccine Advocacy Coalition, USA
Carolyn Williams, NIH, USA
Chris Woodward, Abbott Laboratories, USA
Sheryl Zwerski, NIH, USA